Civil Plaintiff

Bristol-Myers Squibb’s Celgene Unit Backs Out of $55 Million Settlement

Celgene unit, which the big pharma company acquired last year, has backed out of a $55 million settlement agreement with patients and payers over claims that it unfairly thwarted generic drug competition for Thalomid and Revlimid. The patients and payers claim that Celgene blocked generic drug companies from buying the multiple myeloma medications, while also increasing the prices of the drugs.

Generic drug companies need branded medication to do comparison studies with their copycat versions, but Celgene reportedly blocked the companies from buying the drugs because the medicines are covered under a Food and Drug Administration-mandated distribution program called a Risk Evaluation and Mitigation Strategy (REMS), which requires pharmacists and patients to enroll in the REMS program before receiving the drugs.

Read More from Source

    Leave a Review or Comment

    Your email address will not be published. Required fields are marked *

    Back to top button